Status update on the project to adapt and strengthen the Casino Group’s financial structure Status update on the project to adapt and strengthen the Casino Group’s financial structure Paris, 10 February 2026 In order to support the execution of its strategic plan, and in light of the maturity of its debt1, the Group has initiated work to adapt and strengthen its financial structure2. The key terms of the various proposals to adapt and strengthen the Casino Group’s financial structure, as formulated to date, are set out in a presentation published today on Casino’s website (). Should such...
Point d’étape sur le projet d’adaptation et de renforcement de la structure financière du groupe Casino Point d’étape sur le projet d’adaptation et de renforcement de la structure financière du groupe Casino Paris, le 10 février 2026 Afin d’accompagner l’exécution de son plan stratégique, et compte tenu de la maturité de sa dette1, le Groupe a lancé les travaux d'adaptation et de renforcement de sa structure financière2. Les principaux termes des différentes propositions d’adaptation et de renforcement de la structure financière du groupe Casino, telles qu’elles ont été formulées à date,...
Groupe Casino - Nombre total de droits de vote et d'actions au 31-01-2026 CASINO, GUICHARD-PERRACHON Société anonyme au capital de 4 009 397,13 €Siège social : 1, Cours Antoine Guichard42000 Saint-Etienne554 501 171 R.C.S. Saint-Etienne Informations relatives au nombre total de droits de voteet d’actions composant le capital socialau 31 janvier 2026 (article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Nombre d’actions composant le capitalNombre total de droits de voteNombre total de droits de vote exerçables en assemblée générale400 939 713401 185 406400 562 455 * *...
Casino Group Communication Casino Group Communication The Nouveau Casino is not appealing its criminal sentence Paris, 9 February, 2026 Following its sentence on January 29 by the Paris Criminal Court to a fine of 40 million euros, including 20 million euros suspended, for facts dating from 2018-2019, Casino has decided not to appeal this criminal sentence. Casino will contest the calculation of civil damages adopted by the Court. *** ANALYSTS AND INVESTORS CONTACTS Charlotte IZABEL - - Tél : +33 (0)6 89 19 88 33 - Tél : +33 (0)1 53 65 24 17 PRESS CONTACTS Casino Group – Com...
Communication du groupe Casino Communication du groupe Casino Le Nouveau Casino ne fait pas appel de sa condamnation pénale Paris, le 9 février 2026 Suite à sa condamnation le 29 janvier dernier par le Tribunal correctionnel de Paris à une amende de 40 millions d’euros dont 20 millions d’euros avec sursis, pour des faits datant de 2018-2019, Casino a décidé de ne pas faire appel de cette condamnation pénale. Casino contestera le calcul des intérêts civils retenu par le Tribunal. *** CONTACTS ANALYSTES ET INVESTISSEURS Charlotte IZABEL - - Tél : +33 (0)6 89 19 88 33 Relations invest...
Casino Group and Spar International commit to a long-term partnership Casino Group and Spar International commit to a long-term partnership Paris, 5 February 2026 Casino Group announces a major development in its partnership with SPAR International, marking the transition from an agreement that was historically renewable every ten years to an agreement secured until 2039 and designed to continue beyond. Building on nearly 30 years of collaboration, Casino Group and SPAR International have chosen to anticipate the expiry of the current contract in order to place their relationship on a lo...
Le groupe Casino et Spar International s’engagent sur un partenariat de long terme Le groupe Casino et Spar International s’engagent sur un partenariat de long terme Paris, le 5 février 2026 Le groupe Casino annonce une évolution majeure de son partenariat avec SPAR International, marquant le passage d’un accord historiquement renouvelable tous les dix ans à un accord sécurisé jusqu’en 2039 et conçu pour se poursuivre au-delà. Dans la continuité d’une collaboration de près de 30 ans, le groupe Casino et SPAR International ont choisi d’anticiper l’échéance du contrat actuel pour inscrire ...
After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...
Flow Traders: Preview 4Q25 / Kinepolis: January reassures with US box office revenue up 14% YoY, France visitors up 15% YoY / Lotus Bakeries: Peer Mondelez 4Q25 results / MICC: Peer Mondelez 4Q25 results / RELX / Wolters Kluwer: Anthropic moves into Legal / Signify: Analyst lunch highlights / TomTom: 4Q25 results, bridging a gap / UCB: Evenity sales exceeded US$2.1bn in FY25 as per Amgen
UCB announced that three-year data from the BE HEARD trials for Bimzelx in moderate to severe HS will be presented at the Conference of the European Hidradenitis Suppurativa Foundation EHSF, being held 4–6 February in Malta. The data show high rates of total HS resolution at 3 years, high rates of improvement from moderate or severe HS to mild disease, as well as strong draining tunnel resolution. This continues to highlight Bimzelx' benefit in this patient group, which we believe will further d...
Following the second guidance upgrade for FY25 (announced 5 December 2025), we update our UCB model ahead of FY25 results. UCB now expects revenue to exceed €7.6bn, representing +24% y/y (previously at least €7bn). The upgraded guidance reflects - next to the continued growth of Rystiggo, Zilbrysq, Fintepla and Evenity – strong performance of Bimzelx, including a strong momentum in hidradenitis suppurativa (HS) and a favourable payer mix in the US. Our model update increases Bimzelx FY25 sales t...
Friday during trading hours, UCB announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of marketing authorisation under exceptional circumstances for Kygevvi (doxecitine and doxribtimine) for the treatment of pediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years. Following the positive CHMP opinion...
Casino Group Communication Paris, January 29, 2026 Casino Guichard Perrachon takes note of the judgment rendered today by the Paris Criminal Court, which acquitted the Company of the charge of stock price manipulation but sentenced it to the payment of a €40 million fine, of which €20 million is suspended, as well as civil damages, in relation to acts of private corruption and market manipulation dating back to 2018 and 2019. The Company is reviewing the actions it intends to take and reserves the right to appeal before the Paris Court of Appeal. *** ANALYSTS AND INVESTORS CONTACTS ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.